has licensed three pneumococcal conjugate vaccines (PCV15, PCV20, and PCV21) and one pneumococcal polysaccharide vaccine (PPSV23) for protection against pneumococcal disease. A serotype is a ...

Prevenar 13 is a mixture of the outer sugar coating (polysaccharide ... child have ever had an allergic reaction to pneumococcal or diphtheria vaccines, or any of the ingredients listed at ...

NA: Not applicable; PCV-7: 7-valent pneumococcal conjugate vaccine; PCV-13: 13-valent pneumococcal conjugate vaccine; PPV23: 23-valent pneumococcal polysaccharide vaccine.

Participants were randomized to receive a single dose of either one of three lots of CAPVAXIVE or PPSV23 (pneumococcal 23-valent polysaccharide ... 13-valent conjugate vaccine], or cohort 3 ...

polysaccharide-based jab Pneumovax 23. Sanofi's new challenger is billed as a "next-generation" pneumococcal conjugate vaccine that, according to the company, is the first candidate with more than ...

No serious adverse events were considered to be related to the study vaccines. Post-dose 3, the VAX-24 Mid dose met target precedent Phase 2 non-inferiority (NI) criteria on relative ...

Merck & Co – known as MSD outside the US and Canada – has announced that its adult-specific 21-valent pneumococcal conjugate vaccine has been approved by the European Commission (EC). The vaccine, ...

Pneumococcal 20-valent conjugate vaccine (diphtheria CRM197 ... followed 1 month later with 23-valent polysaccharide vaccine (PPSV23). The immune responses to Prevnar 20 in patients aged 18 ...

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for ...

Meanwhile, the launch of new-generation innovative products, including the serum-free rabies vaccine, the 13-valent pneumococcal conjugate vaccine, the quadrivalent meningococcal conjugate vaccine ...

Noninferiority criteria were not met for some pneumococcal conjugate ... Quadrivalent polysaccharide–protein conjugate vaccines against serogroups A, C, W and Y are currently licensed worldwide.